LT2276473T - Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas - Google Patents

Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas

Info

Publication number
LT2276473T
LT2276473T LTEP09754186.6T LT09754186T LT2276473T LT 2276473 T LT2276473 T LT 2276473T LT 09754186 T LT09754186 T LT 09754186T LT 2276473 T LT2276473 T LT 2276473T
Authority
LT
Lithuania
Prior art keywords
carbidopa
levodopa
drug delivery
gastroretentive drug
gastroretentive
Prior art date
Application number
LTEP09754186.6T
Other languages
English (en)
Inventor
Nadav Navon
Eytan Moor
David Kirmayer
Elena Kluev
Giora Carni
Original Assignee
Intec Pharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intec Pharma Ltd. filed Critical Intec Pharma Ltd.
Publication of LT2276473T publication Critical patent/LT2276473T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2873—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
LTEP09754186.6T 2008-04-18 2009-04-17 Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas LT2276473T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4626108P 2008-04-18 2008-04-18
US12005108P 2008-12-04 2008-12-04
PCT/IB2009/005691 WO2009144558A1 (en) 2008-04-18 2009-04-17 Carbidopa/lipodopa gastroretentive drug delivery

Publications (1)

Publication Number Publication Date
LT2276473T true LT2276473T (lt) 2017-02-27

Family

ID=41376643

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP09754186.6T LT2276473T (lt) 2008-04-18 2009-04-17 Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas

Country Status (19)

Country Link
US (6) US8771730B2 (lt)
EP (2) EP3115043B1 (lt)
JP (2) JP2011518148A (lt)
KR (1) KR101601649B1 (lt)
CN (2) CN106176678A (lt)
CA (1) CA2721493C (lt)
CY (1) CY1118296T1 (lt)
DK (1) DK2276473T3 (lt)
ES (2) ES2849873T3 (lt)
HK (1) HK1158545A1 (lt)
HR (1) HRP20161433T1 (lt)
HU (1) HUE030958T2 (lt)
IL (2) IL208708A (lt)
LT (1) LT2276473T (lt)
PL (1) PL2276473T3 (lt)
PT (1) PT2276473T (lt)
SI (1) SI2276473T1 (lt)
WO (1) WO2009144558A1 (lt)
ZA (1) ZA201007797B (lt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2276473T1 (sl) 2008-04-18 2017-02-28 Intec Pharma Ltd. Gastro retencijsko dajanje zdravila karbidope/levodope
ES2740360T3 (es) * 2008-08-15 2020-02-05 Assertio Therapeutics Inc Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
WO2012059815A1 (en) 2010-11-01 2012-05-10 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
US10150792B2 (en) * 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
WO2014099056A2 (en) 2012-12-20 2014-06-26 Carnegie Mellon University Methods and materials for reducing organ transplant rejection or ischemic/reperfusion injury in a subject
CN106535878B (zh) 2014-06-02 2022-11-01 科莱西奥生物科技有限公司 可张开的胃内滞留剂型
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
AU2015274456B2 (en) 2014-06-11 2020-03-26 Massachusetts Institute Of Technology Self-assembled residence devices and related methods
DE102014119576A1 (de) 2014-12-23 2016-06-23 Ernst-Moritz-Arndt-Universität Greifswald Pharmazeutische Arzneimittelform zur Applikation auf Schleimhäuten
WO2016123576A1 (en) 2015-01-30 2016-08-04 Lieber Institute For Brain Development Comt inhibiting methods and compositions
EP3258917B1 (en) 2015-02-19 2022-12-21 Carnegie Mellon University Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
EP3302442A4 (en) * 2015-06-03 2019-02-06 Triastek, Inc. PHARMACEUTICAL FORM AND USE THEREOF
AU2016279997B2 (en) 2015-06-17 2021-10-21 Biogen Ma Inc. Dimethyl fumarate particles and pharmaceutical compositions thereof
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
WO2016205754A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
EP3364946A4 (en) 2015-10-23 2019-06-26 Lyndra, Inc. STOMACH DISTRIBUTION SYSTEMS FOR DELAYED RELEASE OF THERAPEUTIC ACTIVE SUBSTANCES AND METHOD FOR THEIR USE
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
PL3380471T3 (pl) * 2015-11-25 2021-12-20 Lieber Institute Inc. Dba Lieber Institute For Brain Development Tetrahydro-8h-pirydo[1,2-a]pirazyn-8-ony jako inhibitory comt do leczenia chorób i zaburzeń neurodegeneracyjnych
WO2017096054A1 (en) * 2015-12-01 2017-06-08 Teva Pharmaceutical Industries, Ltd. Gastric retentive devices
US11975104B2 (en) 2016-07-11 2024-05-07 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
MX2019000348A (es) 2016-07-11 2019-03-28 Intec Pharma Ltd Formulaciones gastrorretentivas orales y usos de las mismas.
WO2018064630A1 (en) 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
EP3320898A1 (en) 2016-11-11 2018-05-16 ratiopharm GmbH Dosage form comprising a carrier structure and method for manufacturing the dosage form
JP7071748B2 (ja) 2016-12-02 2022-05-19 クレキシオ バイオサイエンシーズ エルティーディー． 胃内滞留システム
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
JP7296084B2 (ja) 2017-12-04 2023-06-22 クレキシオ バイオサイエンシーズ エルティーディー． 長時間作用型胃滞留システム
WO2019137200A1 (en) 2018-01-09 2019-07-18 Triastek, Inc. Oral drug dosage forms comprising a fixed-dose of an adhd non-stimulant and an adhd stimulant
US11638678B1 (en) 2018-04-09 2023-05-02 Vibrant Ltd. Vibrating capsule system and treatment method
US11510590B1 (en) 2018-05-07 2022-11-29 Vibrant Ltd. Methods and systems for treating gastrointestinal disorders
CA3103477A1 (en) 2018-06-19 2019-12-26 National University Of Singapore Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications
CA3125091A1 (en) 2019-01-03 2020-07-09 Vibrant Ltd. Device and method for delivering an ingestible medicament into the gastrointestinal tract of a user
GB201901470D0 (en) 2019-02-04 2019-03-27 Vibrant Ltd Vibrating capsule for gastrointestinal treatment, and method of use thereof
US11147767B2 (en) * 2019-02-25 2021-10-19 Rubicon Research Private Limited Gastroretentive formulations
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
CA3150498A1 (en) * 2019-06-28 2020-12-30 Deven Patel POLYMERIC CONJUGATES OF LEVODOPA, CORRESPONDING FORMULATIONS, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE
CN113116846B (zh) * 2019-12-31 2024-03-19 广州玻思韬控释药业有限公司 胃滞留片
WO2021176361A1 (en) * 2020-03-02 2021-09-10 Craft Health Pte Ltd Method of manufacturing oral dosage forms for extended drug release
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
AU2022320730A1 (en) 2021-07-30 2024-03-14 Evecxia Therapeutics, Inc. 5-hydroxytryptophan gastroretentive dosage forms
WO2023064598A1 (en) 2021-10-14 2023-04-20 Evecxia Therapeutics, Inc. A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
WO2024024865A1 (ja) * 2022-07-28 2024-02-01 大原薬品工業株式会社 レボドパ持続性製剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451260A (en) * 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4767627A (en) * 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
JPH03163011A (ja) * 1989-08-31 1991-07-15 Yamanouchi Pharmaceut Co Ltd 胃内滞留デバイス
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
EP1064937A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
GB9930578D0 (en) * 1999-12-23 2000-02-16 Smithkline Beecham Plc Pharmaceutical formulations
DE10004790B4 (de) 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
CN1520286B (zh) * 2001-07-04 2010-12-01 太阳医药工业有限公司 胃滞留控制药物释出系统
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
EP1523981A1 (en) 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
EP1686976A2 (en) 2003-11-05 2006-08-09 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
IL166183A0 (en) * 2005-01-06 2006-01-15 Yissum Res Dev Co Novel diagnostic and imaging techniques of the gi tract
EP2997953B1 (en) * 2006-01-18 2018-12-26 Intec Pharma Ltd. Delivery device for oral intake of an agent
US20090304768A1 (en) 2006-02-15 2009-12-10 Intec Pharma Ltd Gastro-Retentive System for the Delivery of Macromolecules
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
EP1970056A1 (en) 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
SI2276473T1 (sl) * 2008-04-18 2017-02-28 Intec Pharma Ltd. Gastro retencijsko dajanje zdravila karbidope/levodope
CN101309436B (zh) 2008-07-02 2012-04-18 三一重工股份有限公司 一种无线通信设备匹配认证方法、装置及系统
ES2740360T3 (es) 2008-08-15 2020-02-05 Assertio Therapeutics Inc Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
WO2010064139A2 (en) 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
WO2012059815A1 (en) 2010-11-01 2012-05-10 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
WO2012154986A1 (en) * 2011-05-10 2012-11-15 Antecip Bioventures Ii Llc Implantable polymeric device for sustained release of sufentanil

Also Published As

Publication number Publication date
HK1158545A1 (zh) 2012-07-20
PT2276473T (pt) 2016-12-15
CA2721493A1 (en) 2009-12-03
WO2009144558A1 (en) 2009-12-03
EP3115043A1 (en) 2017-01-11
CA2721493C (en) 2017-11-28
ZA201007797B (en) 2011-07-27
CN102149369A (zh) 2011-08-10
US20160199300A1 (en) 2016-07-14
ES2606395T3 (es) 2017-03-23
EP3115043B1 (en) 2020-11-25
ES2849873T3 (es) 2021-08-23
IL245605A0 (en) 2016-06-30
EP2276473A4 (en) 2013-11-06
CN106176678A (zh) 2016-12-07
US20170119664A1 (en) 2017-05-04
EP2276473B1 (en) 2016-09-14
US8771730B2 (en) 2014-07-08
KR20110015549A (ko) 2011-02-16
HRP20161433T1 (hr) 2017-01-27
JP6062465B2 (ja) 2017-01-18
IL208708A0 (en) 2010-12-30
JP2015154934A (ja) 2015-08-27
JP2011518148A (ja) 2011-06-23
HUE030958T2 (en) 2017-06-28
US20140314842A1 (en) 2014-10-23
SI2276473T1 (sl) 2017-02-28
US20110117192A1 (en) 2011-05-19
US9259387B2 (en) 2016-02-16
DK2276473T3 (en) 2017-01-09
CN102149369B (zh) 2016-08-10
KR101601649B1 (ko) 2016-03-09
US9554991B2 (en) 2017-01-31
US20150366832A1 (en) 2015-12-24
PL2276473T3 (pl) 2017-03-31
EP2276473A1 (en) 2011-01-26
US9072663B2 (en) 2015-07-07
CY1118296T1 (el) 2017-06-28
US20150010624A1 (en) 2015-01-08
IL208708A (en) 2016-05-31

Similar Documents

Publication Publication Date Title
LT2276473T (lt) Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas
HK1218874A1 (zh) 真皮遞送
ZA201104620B (en) Zaleplon gastroretentive drug delivery system
IL215608A0 (en) Drug delivery composition
SG2014007389A (en) Posterior segment drug delivery
EP2339973A4 (en) ACTIVE RELEASE IMPLANTS
PT2307079E (pt) Dispositivo de administração de medicamentos
IL216383A (en) Stable pharmaceutical preparations containing arginine, levodopa and carbidopa
EP2337596A4 (en) MEDICAL INJECTOR EQUIPPED WITH A RATCHET PISTON
ZA200903854B (en) A gastroretentive pharmaceutical dosage form
EP2236149A4 (en) MEDICAL COMPOSITION
EP2323587A4 (en) ACTIVE RELEASE IMPLANTS
IL213577A0 (en) Drug delivery device
HUP0800591A2 (en) Stable pharmaceutical combination
EP2268278A4 (en) PHARMACEUTICAL COMPOSITION
EP2328511A4 (en) ACTIVE RELEASE IMPLANTS
GB0803054D0 (en) Medicament
GB0917359D0 (en) Pharmaceutical composition
GB0817969D0 (en) Pharmaceutical composition
HK1252214A1 (zh) 雙氯芬酸製劑
HK1182939A1 (en) Stable pharmaceutical composition
IL212005A0 (en) Novel gastroretentive delivery system
PL385631A1 (pl) Pompa perystaltyczna
GB0814986D0 (en) Peptide for il10 production
GB0803395D0 (en) Medicament